focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.65
Bid: 5.65
Ask: 5.90
Change: 0.72 (14.60%)
Spread: 0.25 (4.425%)
Open: 4.78
High: 5.65
Low: 4.78
Prev. Close: 4.93
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

18 Jan 2012 07:00

RNS Number : 7281V
Plant Health Care PLC
18 January 2012
 



 

 

18 January 2012

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

 

Trading Update

 

Plant Health Care (AIM: PHC.L), a leading provider of naturally-derived products to the agriculture industry, provides the following post year-end update ahead of the announcement of its full year results to 31 December 2011, which are expected on 27 February 2012. All results provided are preliminary and subject to completion of the 2011 audit.

 

The Board is pleased to report that the operating loss before share-based payments is expected to be approximately $6.7 million, on revenues of $7.9 million. Due to tight control over operating costs, the operating loss was better than expectations, with revenues being slightly less than expectations. As a consequence of the lower losses and strong collections from debtors, the Company is expecting to report cash and cash equivalents at year-end of US$14 million, significantly ahead of expectations. The Company is focused on accelerating the development and improving performance of its core Harpin and Myconate technologies. As a result, R&D spend on next generation product development and formulations doubled in 2011, and is expected to increase at a similar rate in 2012 to over $1mm.

 

The Company has also been strongly focused on the pursuit of further significant partnering relationships. The following is a progress report on the most significant aspects of the business:

 

·; On-ground sales (end-user application of the product) of Harpin in the US rose approximately 40% in 2011 from programmes driven by the Company and its partners to increase market awareness and acceptance of Harpin as a critical biological enhancement to existing seed treatment options. As a result of in-hand distributor orders, we expect 2012 on-ground sales to more than triple 2011 levels. On-ground sales of Harpin have also grown rapidly in Mexico and South Africa as a result of initiatives in those markets. Both countries experienced roughly 50% growth in on-ground sales in 2011, and we expect this to accelerate by 70% in 2012.

·; As a result of the success of on-ground sales, Plant Health Care is in discussions with a number of global and regional agrichemical and agricultural supply companies to further exploit its Harpin and Myconate technologies, on new crops, by new product applications and in new geographical regions. Good progress is being made towards finalising substantial new partnering agreements during 2012.

·; 2011 delivered the best set of trial results with Harpin and Myconate that the Company has ever experienced. The strength of these results has helped escalate our partnering discussions.

·; We have developed six next generation Harpin product candidates that will be moving into initial field trials in 2012. All six candidates have exhibited significantly stronger attributes in greenhouse trials than the Harpin products that are currently in the market.

 

The Board has been greatly encouraged by the progress made in the past 12 months and believes that the increasing use of Harpin and Myconate-based products and the pipeline of potential new partnering transactions will ensure that our present cash resources will be sufficient to fund the Company through to profitability in future periods.

 

 

John Brady, Chief Executive of Plant Health Care, said: "The sale of the US retail and landscape business at the start of 2011 has allowed us to focus on obtaining licensing agreements for Harpin and Myconate and on supporting our partners in the introduction of new products. Good progress across the business and our strong trial results mean we remain confident of substantial progress and further important developments during 2012."

 

-Ends-

For further information please contact:

 

Plant Health Care plc 

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications

Jeremy Ellis

Jeremy Carey/Simon Compton

Tel: +44-20-7071-4300

Tel: +44-20-7920-3150

 

jeremy.ellis@evosecurities.com

 

jcarey@tavistock.co.uk

scompton@tavistock.co.uk

 

Notes to editors:

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 40 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands.

 

The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/ mnemonic: PHC).

 

Trademarks:

Myconate and Harpin are trademarks or trade names which Plant Health Care owns or which others own and license to Plant Health Care for use.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBUBRUVAAAAR
Date   Source Headline
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.